Investigating the Panax ginseng proteome using an in silico method to find bioactive peptides that can alter the dynamics of breast cancer carcinogenesis
DOI:
https://doi.org/10.22456/2527-2616.139143Keywords:
Panax ginseng, Proteome analysis, In-silico methods, Bioactive peptides, Breast cancer carcinogenesisAbstract
Breast cancer is a major public health concern throughout the world, particularly in Cameroon. Numerous modalities, including surgery, radiotherapy, and chemotherapy, have been used for clinical cancer therapy. Despite advances in anti-cancer therapies, the use of these methods to treat cancer is often associated with deleterious side effects and multi-drug resistance to conventional anti-cancer drugs, which has led to the development of new therapeutic methods, anti-cancer peptides (ACP). The aim of this study was to produce peptides that could be potential modulators of breast cancer, using in silico prediction as complementary tool. Several techniques were applied to achieve this goal: Protein hydrolysis, protein-peptide molecular docking, and target prediction have all been employed as techniques. It has been determined that 156 genes may play a role in the carcinogenesis of breast cancer. Ten (10) kinases (CDK1, NLK, CDK4, CDK2, CSNK2A1, GSK3B, HIPK2, MAPK14, CK2ALPHA, and MAPK1) and 10 transcription factors (TRIM28, CHD1, SOX2, NANOG, UBTF, TCF7L2, TCF3, CTCF, SUZ12, and NFE2L2) were identified as involved in the process of breast cancer carcinogenisis. Only nineteen of the 1324 peptides that were synthesised exhibited an affinity of greater than 20%, and approximately twenty-eight distinct proteins were found. The peptides AIF, AIN, APQVAVL, ESK, IAK, PSIPK, PVGF, and SDTEL are all intriguing candidates for additional research, according to the overall findings. The study's non-allergic peptides had binding energy values of less than or equal to -5.00 kcal.mol. Future studies will use both in vitro and in vivo methods to examine the positive effects of hydrolyzed peptides.
Downloads
References
Sarhangi N, Hajjari S, Heydari SF, Ganjizadeh M, Rouhollah F, Hasanzad M. Breast cancer in the era of precision medicine. Mol Biol Rep. 2022;49(10):10023-10037.
Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186(8):1708-1728.
Bray F, Parkin DM; African Cancer Registry Network. Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs. Lancet Oncol. 2022;23(6):719-728.
Anyigba CA, Awandare GA, Paemka L. Breast cancer in sub-Saharan Africa: The current state and uncertain future. Exp Biol Med (Maywood). 2021;246(12):1377-1387.
Rochefort H. Cancérogenèse hormonale chez la femme: des mécanismes à la prévention [Hormonal carcinogenesis in women: from mechanisms to prevention]. C R Biol. 2008;331(2):104-113.
Yang Z, Zhang Q, Yu L, Zhu J, Cao Y, Gao X. The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J Ethnopharmacol. 2021;264:113249.
Libert EEE, Awalou H, Oyono JLE. Investigation of active peptides from natural products that induce ERstress-mediated apoptosis in cancer as potential therapeutics for kidney cancer, common in some genetic diseases: An in silico approach. Journal of Drug Delivery and Therapeutics. 2023;13(11):111- 120.
Ounaissia K, Bechiri R, Snani M, Naoun L. Plantes médicinales utilisées contre le cancer du sein par la population d’Algérie de l’Est. Phytothérapie. 2021;19(5-6):379-396.
Barton DL, Soori GS, Bauer BA, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer. 2010;18(2):179-187.
Manrique-Moreno M, Santa-González GA, Gallego V. Bioactive cationic peptides as potential agents for breast cancer treatment. Biosci Rep. 2021;41(12):BSR20211218C.
Li X, Gao B, Su X. Anticancer bioactive peptide combined with docetaxel and its mechanism in the treatment of breast cancer. Exp Ther Med. 2020;20(3):1917-1924.
AL Shabanah OA, Alotaibi MR, Al Rejaie SS, et al. Inhibitory Effect of Ginseng on Breast Cancer Cell Line Growth Via Up-Regulation of Cyclin Dependent Kinase Inhibitor, p21 and p53. Asian Pac J Cancer Prev. 2016;17(11):4965-4971. Published 2016 Nov 1.
Kim S, Kim N, Jeong J, Lee S, Kim W, Ko S-G, Kim B. Anti-Cancer Effect of Panax Ginseng and Its Metabolites: From Traditional Medicine to Modern Drug Discovery. Processes. 2021; 9(8):1344.
Kim TH, Kwon SC, Kim JN, Yoon JH, Cho SG. Ginseng Seed Oil Inhibits the Growth of Estrogen Receptor-positive Breast Cancer Cells. Anticancer Res. 2020;40(8):4529-4535.
Jayakodi M, Choi BS, Lee SC, et al. Ginseng Genome Database: an open-access platform for genomics of Panax ginseng. BMC Plant Biol. 2018;18(1):62. Published 2018 Apr 12.
Wilkinson JC, Cepero E, Boise LH, Duckett CS. Upstream regulatory role for XIAP in receptormediated apoptosis. Mol Cell Biol. 2004;24(16):7003- 7014.
Cata JP, Uhelski ML, Gorur A, Bhoir S, Ilsin N, Dougherty PM. The µ-Opioid Receptor in Cancer and Its Role in Perineural Invasion: A Short Review and New Evidence. Adv Biol (Weinh). 2022;6(9):e2200020.
Nair MG, Prabhu JS, Ts S. High expression of ACE2 in HER2 subtype of breast cancer is a marker of poor prognosis. Cancer Treat Res Commun. 2021;27:100321.
Sahu A, Raza K, Pradhan D, Jain AK, Verma S. Cyclooxygenase-2 as a therapeutic target against human breast cancer: A comprehensive review. WIREs Mech Dis. 2023;15(3):e1596.
Stephen HM, Khoury RJ, Majmudar PR, et al. Epigenetic suppression of neprilysin regulates breast cancer invasion. Oncogenesis. 2016;5(3):e207. Published 2016 Mar 7.
Gudmundsdóttir I, Gunnlaugur Jónasson J, Sigurdsson H, Olafsdóttir K, Tryggvadóttir L, Ogmundsdóttir HM. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer. 2000;89(6):500-505.
Sun L, Ding H, Jia Y, et al. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. Breast Cancer Res. 2022;24(1):12. Published 2022 Feb 12.
Liu J, Li P, Wang R, et al. High expression of DLG3 is associated with decreased survival from breast cancer. Clin Exp Pharmacol Physiol. 2019;46(10):937-943.
Linders DGJ, Bijlstra OD, Fallert LC, et al. Cysteine Cathepsins in Breast Cancer: Promising Targets for Fluorescence-Guided Surgery. Mol Imaging Biol. 2023;25(1):58-73.
Coveñas R, Rodríguez FD, Muñoz M. The Neurokinin-1 Receptor: A Promising Antitumor Target. Receptors. 2022; 1(1):72-97.
E B, H C, S V, CM C. Lipoxin A4 a novel therapeutic agent for the treatment of breast cancer metastases. Integrative Cancer Science and Therapeutics. 2020;7(3).
Kotalwar KS, Deshmukh AV, Gangane NM. Role of Caspase-8 as a prognostic biomarker in breast cancer—A pilot study in central India. Indian J Gynecol Oncol. 2021;19(4):74.
Downloads
Published
Versions
- 26-03-2026 (2)
- 19-07-2024 (1)
How to Cite
Issue
Section
License
Copyright (c) 2024 Drug Analytical Research

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Copyright holder of manuscripts published is Drug Analytical Research. Authors who publish with this journal are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Licensing:
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.





